

Mergers and Acquisitions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions around the globe. Our M&A practice comprises an interdisciplinary team of lawyers in key geographic markets, who deliver responsive and practical solutions on transactions in an increasingly complex and challenging environment. Applying a holistic approach, we bring together our seasoned teams to provide guidance in areas including corporate/M&A, securities, governance, strategic response, antitrust, intellectual property, labor and employment, benefits, tax, and regulatory.

PRACTICE AT A GLANCE

- Represent leaders in life sciences, technology, defense, communications, financial services and other industries, who turn to WilmerHale for legal advice and business advantage.
- Routinely work on strategic transactions for sophisticated serial acquirors, including Akamai Technologies, Analog Devices, Danaher, Medtronic, MKS Instruments, Revvity (FKA PerkinElmer) and Thermo Fisher Scientific, where we integrate closely with our clients' internal teams.
- Serve as outside counsel to numerous public and venture-backed life sciences and technology companies, giving us a unique perspective into IP and tech-driven M&A deals.
- Represent private companies, underwriters, financial advisors, placement agents and private equity, venture capital, family offices and other investors in SPAC transactions and SPAC-related PIPEs and other investments.

THE WILMERHALE DIFFERENCE

- Senior partner focus
- Commitment to efficiency and value
- Creativity to solve the most complex problems and bridge gaps
- Focus on long-term relationships
- Willingness to share risk through alternative fee arrangements

RECOGNITIONS



Chambers USA: America's Leading Lawyers for Business has consistently ranked our Corporate/M&A practice in Band 1.



The Legal 500 United States recommended WilmerHale's Mergers and Acquisitions practice for our work in the area of M&A: middle-market (\$500M–999M) in its 2010–2023 editions.

"Well-regarded corporate and M&A practice" with a "longstanding pedigree in advising clients in complex and highly regulated industries."

— Chambers USA (2023)

SELECT EXPERIENCE

- **Acacia Communications** acquisition by Cisco Systems for \$4.5 billion
- Adore Me acquisition by Victoria's Secret & Co. for \$400 million, plus up to \$300 million in post-closing payments
- Affirmed Networks acquisition by Microsoft for \$1.4 billion
- Akamai Technologies numerous acquisitions including Linode for \$900 million, Guardicore for \$600 million, and Prolexic Technologies for \$403 million
- Akouos acquisition by Eli Lilly for \$610 million
- Altimeter Capital Management acquisition of Grab by Altimeter Growth for \$39.6 billion
- Amplitude Healthcare Acquisition Corporation business combination with Jasper Therapeutics, valued at \$490 million
- Bottomline Technologies (co-counsel) acquisition by Thoma Bravo for \$2.6 billion
- **Disarm Therapeutics** acquisition by Eli Lilly for up to \$1.225 billion
- **Eaton Vance** acquisition by Morgan Stanley for \$7 billion
- Emisphere Technologies (special committee) acquisition by Novo Nordisk A/S for \$1.8 billion
- **Endurance** acquisition by Clearlake Capital Group L.P. for \$3 billion
- **Fortive** acquisition of Service Channel for \$1.2 billion
- General Catalyst merger of Livongo and Teladoc Health, valued at \$18.5 billion, and sale of its portfolio company Clarabridge for \$1.125 billion
- Houghton Mifflin Harcourt acquisition by affiliates of Veritas Capital for \$2.8 billion
- MKS Instruments numerous acquisitions including Atotech for \$4.4 billion (financing counsel), Electro Scientific Industries for \$1 billion and the proposed acquisition of Coherent for \$6.1 billion
- Revvity (FKA PerkinElmer) numerous acquisitions and divestitures including
 the sale of its Applied, Food and Enterprise Services businesses to New Mountain
 Capital for \$2.45 billion, and purchases of BioLegend for \$5.25 billion and Oxford
 Immunotec for \$591 million
- Progress Software acquisitions of Kemp Technologies for \$258 million,
 Ipswitch, Inc. for \$225 million and Chef for \$220 million
- The Tecan Group acquisition of Paramit Corporation for \$1 billion
- Thermo Fisher Scientific numerous acquisitions and divestitures including the purchase of PPD for \$20.9 billion (debt financing counsel), Phadia Group for \$3.5 billion, Propel Labs for \$220 million, and the sale of its Anatomical Pathology and Cell Culture businesses for \$1.1 billion and \$1 billion, respectively
- WEX –numerous acquisitions including EFS for \$1.4 billion, eNett and Optal for \$1.275 billion, and benefitexpress for \$275 million

For more information, please contact:

Hal J. Leibowitz — Partner | +1 617 526 6461 | hal.leibowitz@wilmerhale.com **Joseph B. Conahan** — Partner | +1 617 526 6317 | joseph.conahan@wilmerhale.com

TRANSACTION TYPES

- Mergers
- Stock and asset acquisitions
- Dispositions
- Corporate auctions
- Tender and exchange offers
- Acquisitions of troubled companies
- Corporate reorganizations and restructurings
- Joint ventures
- Proxy contests
- Leveraged and management buyouts
- Spin-offs
- SPAC (special purpose acquisition company) business combinations

800+

M&A deals totaling more than \$450B in the past decade

100+

publicly traded companies for which we serve as outside counsel